Role of the Insulin-Like Growth Factor I Decline in the Induction of Atrogin-1/MAFbx during Fasting and Diabetes
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In catabolic conditions, atrogin-1/MAFbx, a muscle-specific ubiquitin-ligase required for muscle atrophy, is increased, and concentrations of IGF-I, a growth factor known to have antiproteolytic action, are reduced. To define the relationship between the decline in IGF-I and the induction of atrogin-1/MAFbx, we studied the effect of IGF-I replacement on atrogin-1/MAFbx mRNA in rats fasted for 51 h and in rats made diabetic with streptozotocin (STZ). Fasting produced a 5.8-fold increase in atrogin-1/MAFbx (P < 0.001). This was attenuated to a 2.5-fold increase by injections of IGF-I (P < 0.05 vs. fasting). Animals with STZ-induced diabetes experienced a 15.1-fold increase in atrogin-1/MAFbx (P < 0.001). Normalization of their circulating IGF-I concentrations by IGF-I infusion blunted the induction of atrogin-1/MAFbx to 6.3-fold (P < 0.05 vs. STZ diabetes without IGF-I). To further delineate the regulation of atrogin-1/MAFbx by IGF-I, we studied a model of cultured muscle cells. We observed that IGF-I produced a time- and dose-dependent reduction of atrogin-1/MAFbx mRNA, with a 50% effective dose of 5 nm IGF-I, a physiological concentration. The degradation rate of atrogin-1/MAFbx mRNA was not affected by IGF-I, suggesting that the reduction of atrogin-1/MAFbx mRNA by IGF-I is a transcriptional effect. Exposure of muscle cells in culture to dexamethasone increased atrogin-1/MAFbx mRNA with a 50% effective dose of 10 nm, a pharmacological concentration. In the presence of dexamethasone, IGF-I at physiological concentrations retained its full inhibitory effect on atrogin-1/MAFbx mRNA. We conclude that IGF-I inhibits atrogin-1/MAFbx expression and speculate that this effect might contribute to the antiproteolytic action of IGF-I in muscle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521 · cited 10×
“4808 Endocrinology, November 2004, 145(11):4806–4812 Dehoux et al.”
InfluentialSandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012
Stitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyva, Y., Kline, W. O., Gonzalez, M., Yancopoulos, G. D., & Glass, D. J. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00211-4 · Cited by 1,964
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression
Lecker, S. H., Jagoe, R. T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S. R., Mitch, W. E., & Goldberg, A. L. (2004) · The FASEB Journal · doi:10.1096/fj.03-0610com · Cited by 1,539
Protein dynamics in whole body and in splanchnic and leg tissues in type I diabetic patients.
Nair, K. S., Ford, G. C., Ekberg, K., Fernqvist-Forbes, E., & Wahren, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118000 · Cited by 239
Cited by
Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1
Bodine, S. C., & Baehr, L. M. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00204.2014 · Cited by 1,113
Glucocorticoid-Induced Skeletal Muscle Atrophy
Schakman, O., Kalista, S., Barbé, C., Loumaye, A., & Thissen, J. P. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.036 · Cited by 705
“…(lysosomal, roteasomal and calpain-dependent) and the expression of Atroenes such as Atrogin-1, MuRF-1, Cathepsin-L induced by GC in yotubes (Dehoux et al., 2004; Latres et al., 2005; Li et al., 2005). econd, IGF-I suppress the muscle cell atrophy caused by GC in vitro Li et al., 2005;…”
BackgroundMechanisms of glucocorticoid-induced myopathy
Schakman, O., Gilson, H., & Thissen, J. P. (2008) · Journal of Endocrinology · doi:10.1677/joe-07-0606 · Cited by 521
Self-citationMolecular and cellular mechanisms of skeletal muscle atrophy: an update
Fanzani, A., Conraads, V. M., Penna, F., & Martinet, W. (2012) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-012-0074-6 · Cited by 370
The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy
Foletta, V. C., White, L. J., Larsen, A. E., Léger, B., & Russell, A. P. (2011) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-010-0919-9 · Cited by 357
Metabolic Actions of Insulin-Like Growth Factor-I in Normal Physiology and Diabetes
Clemmons, D. R. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.017 · Cited by 297
The role of E3 ubiquitin-ligases MuRF-1 and MAFbx in loss of skeletal muscle mass
Rom, O., & Reznick, A. Z. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.12.031 · Cited by 256
Porporato, P. E., Payen, V. L., De Saedeleer, C. J., Préat, V., Thissen, J.-P., Feron, O., & Sonveaux, P. (2012) · Angiogenesis · doi:10.1007/s10456-012-9282-0 · Cited by 255
Self-citationLipid modulation of skeletal muscle mass and function
Lipina, C., & Hundal, H. S. (2017) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12144 · Cited by 247
Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass
Frost, R. A., & Lang, C. H. (2007) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00089.2007 · Cited by 200
Krause, M. P., Riddell, M. C., & Hawke, T. J. (2011) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2010.00699.x · Cited by 188
“Interestingly, the plasma concentration of IGF-1 is reduced in T1DM (84, 162, 163), even with insulin treatment (164).”
BackgroundDiabetes, Sarcopenia, and Frailty
Morley, J. E. (2008) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2008.03.004 · Cited by 186
“The decline in IGF-1 in diabetic animal models results in a sixfold increase in atrogene activation with a subsequent increase in proteolysis [83].”
BackgroundHudson, M. B., Woodworth-Hobbs, M. E., Zheng, B., Rahnert, J. A., Blount, M. A., Gooch, J. L., Searles, C. D., & Price, S. R. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00266.2013 · Cited by 137
“Our group previously found that Cn/NFAT signaling was reduced in skeletal muscle during acute streptozotocin (STZ)-induced diabetes, a condition associated with increased atrogin-1 and MuRF1 expression and muscle wasting (5, 8, 10).”
Ono, T., Takada, S., Kinugawa, S., & Tsutsui, H. (2015) · Experimental Physiology · doi:10.1113/ep085049 · Cited by 99
“These deficiencies or reduced reactivity are thought to be involved in skeletal muscle atrophy (Dehoux et al. , 2004).”
Skeletal muscle atrogenes: From rodent models to human pathologies
Taillandier, D., & Polge, C. (2019) · Biochimie · doi:10.1016/j.biochi.2019.07.014 · Cited by 66
Castillero, E., Martín, A. I., López-Menduiña, M., Villanúa, M. A., & López-Calderón, A. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00388.2009 · Cited by 53
Oral L-Glutamine Pretreatment Attenuates Skeletal Muscle Atrophy Induced by 24-h Fasting in Mice
de Vasconcelos, D. A. A., Giesbertz, P., de Souza, D. R., Vitzel, K. F., Abreu, P., Marzuca-Nassr, G. N., Fortes, M. A. S., Murata, G. M., Hirabara, S. M., Curi, R., et al. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.05.010 · Cited by 33
Pinheiro, C. H. J., Guimarães-Ferreira, L., Gerlinger-Romero, F., & Curi, R. (2013) · Nutrition and Enhanced Sports Performance · doi:10.1016/b978-0-12-396454-0.00047-3 · Cited by 7
Metadata
- Authors
- Dehoux, M., Van Beneden, R., Pasko, N., Lause, P., Verniers, J., Underwood, L., Ketelslegers, J.-M., & Thissen, J.-P.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2004-11-01
- Volume
- 145
- Issue
- 11
- Pages
- 4806-4812
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1983738917
- Cited by
- 147
- References
- 5
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.